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 Non-invasive prenatal screening (NIPS) has rapidly grown in uptake since its 
introduction to clinical practice in 2011.  In contrast to more traditional methods of 
screening, NIPS is the first to utilize cell-free fetal DNA for risk assessment of 
chromosomal aneuploidy and other conditions.  Clinical validity has been established for 
the most common autosomal aneuploidies (Trisomy 21, Trisomy 18, and Trisomy 13) 
and sex chromosome aneuploidies, though some laboratories screen for conditions 
beyond these.  A screen positive does not always indicate a true positive, therefore 
professional guidelines recommend diagnostic testing for confirmation and informed 
decision making on pregnancy management.  Furthermore, the methodology of NIPS 
means a positive result could be maternal or placental in origin and not necessarily 
represent the fetus.  It is also possible to get a no call result that could suggest another 
genetic aberration, at which point patients and providers are left to follow up at their own 
discretion due to the lack of management guidelines.  The goal of our study was to track 
pregnancy outcomes for patients receiving abnormal NIPS results, and use those 
outcomes to develop follow-up protocol for our practice.  Additionally, we sought to 
make novel correlations for no call results.  One hundred eighty one women were eligible 
for inclusion after medical record review.  Consistent with other research, the greatest 
number of true positives were for autosomal aneuploidies.  Patients’ uptake of diagnostic 
testing was impacted by the individual result type, presence of ultrasound abnormalities, 
and laboratories’ indications of a maternal or fetal abnormality.  During the course of our 
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study, some laboratories began specifying reasons for no calls.  This was helpful in 
guiding management, as certain types of no calls were more strongly associated with 
abnormalities and/or adverse fetal outcomes.  Several no call results in our study led to 
the identification of genetic aberrations in both fetuses and mothers, suggesting the 
importance of follow-up and appropriate management.  Overall, our study reiterates the 
importance of diagnostic testing as confirmation for screen positives, contributes 
outcome data to the growing incidence of abnormal NIPS results, and provides follow-up 
recommendations based on each result type.
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1.1 What is NIPS? 
Non-invasive prenatal screening (NIPS) has rapidly grown in uptake since its 
introduction to clinical practice in 2011 (Palomaki et al., 2011).  Arguably replacing more 
traditional methods of prenatal screening for chromosomal abnormalities such as the first 
trimester screen (FTS), NIPS analyzes cell-free fetal DNA (cfDNA) found circulating in 
maternal blood.  This cfDNA originates from the placenta and presumably represents the 
fetus.  Multiple clinical studies have deemed it valid for screening for the most common 
autosomal aneuploidies present at birth (Trisomy 21, Trisomy 18, and Trisomy 13) as 
well as sex chromosome aneuploidies (SCAs).  While certain laboratories have begun 
including cfDNA screening for triploidy, copy number variants 
(microdeletions/microduplications), and forms of aneuploidy not viable in pregnancy 
(such as Trisomy 16 or Trisomy 22), inclusion of these conditions on NIPS is not 
recommended by the American College of Obstetricians and Gynecologists (ACOG) or 
the American College of Medical Genetics (ACMG) at this time (ACOG, 2016; Gregg et 
al., 2016).  
1.2 Methodologies 
 There are two main methodologies used to conduct cfDNA screening.  The first is 
colloquially known as the counting method, which can be broken down into 
subcategories of massively parallel sequencing (MPS) and targeted sequencing.  MPS 
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amplifies and sequences maternal and placental DNA fragments from across the genome.  
While this allows greater depth of coverage, it also increases the number of false results 
(Avram, Shaffer, Sparks, Allen, & Caughey, 2019).  Targeted sequencing reads only 
regions of interest and can therefore be considered more efficient.  The second platform 
is single-nucleotide polymorphism (SNP) based, which also only sequences gene regions 
of interest.  It determines copy number in each gene region, compares the allelic 
measurements, and then proceeds through an algorithm.  A meta-analysis conducted by 
Yaron (2016) found that MPS had a lower failure rate (1.58%) than SNP-based platforms 
(6.39%).  However, the SNP-based platform boasts the ability to identify triploidy, 
vanishing twins, and distinguish between monozygotic and dizygotic twins (Curnow et 
al., 2015; Mathieson & Roy, 2018; Norwitz et al., 2019).    
1.3 Conditions screened 
 Clinical validity has been established for the most common autosomal 
aneuploidies present at birth (Trisomy 21, Trisomy 18, and Trisomy 13) and SCAs, and 
some laboratories are offering copy number variants (CNVs), triploidy, and other forms 
of nonviable aneuploidies as well.  The sensitivity of Down syndrome is the highest 
performing, with estimates consistently hovering around 99% (ACOG, 2016; Gil, 
Quezada, Revello, Akolekar, & Nicolaides, 2015; Mackie, Hemming, Allen, Morris, & 
Kilby, 2017).  Other estimates include 96-98% for Trisomy 18 and 90-91% for Trisomy 
13 (ACOG, 2016; Gil et al., 2015; Mackie et al., 2017).  The sensitivity of SCAs does not 
seem to lag far behind, though data for these are more limited.  Gil et al. (2015) found a 
90.2% detection rate of Monosomy X (Turner syndrome), and a 93% pooled detection 
rate for other SCAs.  The positive predictive value (PPV) for these conditions has been 
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reported in a range: 65-94% for Trisomy 21, 47-85% for Trisomy 18, and 12-62% for 
Trisomy 13 (Hu et al., 2019).  Additionally, the PPV of SCAs has been reported to range 
from 25-75% (Fleddermann et al., 2019; Zhang et al., 2019).   
 Though some laboratories have begun screening for CNVs against the 
recommendation of professional guidelines, available data on performance detection are 
few.  Interestingly, one study considered the cost-effectiveness of including these 
conditions on NIPS, and found that it was indeed financially practical (Avram et al., 
2019).  However, inclusion on NIPS would still lend itself to low PPVs due to the overall 
low prevalence of these conditions.   
1.4 Possible results 
 1.4.1 Screen positive 
 As opposed to FTS generating an adjusted risk estimate such as 1 in 50, NIPS will 
indicate screen positive, screen negative, or no-call.  Per ACOG and ACMG 
recommendations, screen positive results should be followed up with the offer of 
diagnostic testing and detailed ultrasonography to evaluate for fetal abnormalities 
(ACOG, 2016; Gregg et al., 2016).  Occasionally, positive results may indicate maternal 
conditions, confined placental mosaicism, or vanishing twins and therefore not be 
representative of the pregnancy.  This is a well-described limitation of NIPS that 
emphasizes the importance of diagnostic testing to confirm that the positive result 





1.4.2 Screen negative 
A screen negative result significantly reduces but does not eliminate the chance 
for a fetus to be affected by one of the conditions screened.  Patients are generally given a 
residual risk, often less than 1 in 10,000.  
 1.4.3 No call 
A no call or failed result occurs in 0.5-3.0% of cfDNA screens, presenting a 
challenge for genetic counselors (GCs) and maternal-fetal medicine specialists (MFMs) 
(Qiao et al., 2019).  The most common reason for a failed NIPS is insufficient fetal 
fraction (FF).  Fetal fraction describes the proportion of DNA in maternal circulation that 
is of placental origin and thought to represent the pregnancy.  Three to thirteen percent is 
generally regarded as the acceptable range for cfDNA analysis (ACOG, 2016; Qiao et al., 
2019).  If the amount of cfDNA falls below this threshold, NIPS will most likely be 
unsuccessful.  Multiple studies have evaluated the success of a redraw in generating a 
screen positive or negative result, however, this is not a perfect solution to low FF cases, 
as many still do not receive a result after a second attempt.   
 A second reason NIPS may fail to produce a result is due to an uninformative 
DNA pattern.  An uninformative DNA pattern describes the situation in which the DNA 
of the mother or fetus is unable to be analyzed.  Multiple explanations as to why the DNA 
pattern may be uninformative have been put forward.  These include the type of 
pregnancy (egg donor, surrogacy, or multiple gestations), vanishing twins, fetal or 
maternal mosaicism, maternal malignancy, increased stretches of homozygosity, 
sampling error, or fetal aneuploidy.  Unlike cases of low fetal fraction, a redraw is 
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generally not requested by performing laboratories.  Instead, clinicians are left to follow 
up at their own discretion.   
NIPS may also fail due to processing errors by the performing laboratory or 
collection errors through the phlebotomy laboratory.  In these circumstances, a redraw is 
recommended.   
1.5 Integration into clinical practice 
 The introduction of NIPS into clinical practice has decreased utilization of 
traditional maternal serum screening (MSS) methods.  Providers and patients are drawn 
to the higher sensitivities of NIPS, as well as its advantage to predict gender as early as 
nine weeks.  Providers still offering traditional screening options may value NIPS as a 
second-tier screen.  It can serve as an optional next step in risk assessment following a 
positive serum screen; however, professional guidelines still recommend prenatal 
diagnosis for confirmation (ACOG, 2016; Gregg et al., 2016).  Logistical considerations 
may also dictate what screening is ultimately chosen by the patient.  A prime example of 
this is varying insurance coverage of NIPS, especially for individuals not considered 
high-risk (e.g. women below advanced maternal age) (Farrell, Agatisa, Michie, Greene, 
& Ford, 2019).     
 Because NIPS has a higher sensitivity than MSS, uptake of diagnostic testing has 
decreased as well.  While still offered, chorionic villus sampling and amniocentesis 
procedures are often declined given the associated risks.  Providers and patients may 
view NIPS results as a reason not to proceed with diagnostic testing, especially in the 
presence of ultrasound abnormalities or other clues that the positive screen is indeed a 
true result.  However, professional societies remain firm in their guidelines that 
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pregnancy management decisions should not be based on NIPS results.  Diagnostic 
testing is still the standard recommended follow-up to any screen positive result or 
ultrasound finding; it serves to not only confirm the diagnosis, but also to distinguish 
aneuploidy resulting from a nondisjunction event or translocation, which influences 
counseling on recurrence risk (ACOG, 2016; Gregg et al., 2016).   
1.6 Challenges of screen positive results 
 1.6.1 Unknown etiology  
 The foundational challenge of screen positive NIPS results is that the positive 
result could represent one of many variables: fetal DNA, maternal DNA, confined 
placental mosaicism, a vanished twin, or maternal malignancy.  Confined placental 
mosaicism (CPM) is thought to impact 1-2% of all pregnancies.  Hartwig, Ambye, 
Sorenson, and Jorgensen (2017) found that CPM could explain 39% of false positive 
NIPS results.  Vanishing twins can also be a plausible explanation for screen positive 
results, as upwards of 70% of spontaneous abortions are due to chromosome 
abnormalities (Suzumori & Sugiura-Ogasawara, 2010).  Additionally, Hartwig and 
colleagues (2017) found maternal mosaicism or maternal CNVs to be responsible for 
over half of false positive NIPS results.  This suggests that while maternal chromosome 
analysis is a reasonable next step, diagnostic testing remains the standard follow-up for 
fetuses, and conditions cannot be confirmed or ruled out without it. 
 1.6.2 Varying severity of autosomal aneuploidies   
 Beyond this foundational challenge, there are other considerations for screen 
positive results based on the type of condition indicated.  The autosomal aneuploidies 
(Trisomies 21, 18, and 13) have higher PPVs and can sometimes be corroborated by 
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ultrasound findings, including soft markers (Ebrashy et al., 2016).  Zhen, Li, Yang, and 
Li (2019) reported that 94.6% of confirmed Trisomy 18 cases and 100% of Trisomy 13 
cases demonstrated ultrasound abnormalities prior to diagnostic testing; thus, their 
finding is that ultrasound is significant in adjusting the PPV for screen positive Trisomy 
18 or Trisomy 13 results.  Ultrasound for Trisomy 21 is less reliable, however; only about 
50% of cases will have findings during a second trimester scan (ACOG, 2016).  
Additionally, the conversation that GCs have with patients regarding a screen positive 
Trisomy 21 result can differ from the conversation had over a screen positive Trisomy 18 
or Trisomy 13 result.  Trisomy 21 (Down syndrome) is generally described as a condition 
in which individuals have variable medical complications and learning difficulties due to 
the presence of an extra chromosome, whereas Trisomy 18 and Trisomy 13 are generally 
described as life-limiting conditions.  While thoughts on pregnancy management can be 
facilitated and discussed in the context of any screen positive result, Trisomy 18 and 
Trisomy 13 are conditions in which palliative care and/or surgical intervention options 
are particularly relevant to discuss.  
 1.6.3 Sex chromosome aneuploidies 
 Screen positive results for SCAs are especially difficult to manage.  There are no 
consistent guidelines for screen positive follow-up, and, compared to the autosomal 
aneuploidies, they have lower PPVs and usually no ultrasound findings to aid in 
screening interpretation.  As SCAs tend to be associated with more social and 
developmental challenges, it is unusual to identify structural malformations; however, a 
known exception to this is Monosomy X (Turner syndrome) in which heart and renal 
differences can be identified prenatally.  
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 A screen positive SCA can also be indicative of a maternal condition, which 
warrants further testing to aid in result interpretation.  Current literature suggests that 
offering maternal karyotypes in the context of screen positive SCA results is done 
inconsistently, even though it has been reported that 8.6% of screen positives are 
attributable to maternal SCAs (Fleddermann et al., 2019; Wang et al., 2015).  A separate 
study by Zhang et al. (2019) reported that the rate of maternal sex chromosome 
differences (full aneuploidy or CNVs) in screen positive SCAs was 21/86, or 24.42%.  
 1.6.4 Microdeletion and microduplication syndromes 
 Positive results indicating microdeletion or microduplication syndromes are 
challenging as well.  The PPVs for these CNVs are described as low to moderate until 
further studies can better define their performance on NIPS (Liang et al., 2019).  While 
reports of CNVs being detected on NIPS are few, Hu et al. (2019) released data 
indicating that the PPV of their screen positive CNVs on a genome-wide platform was 
36.11%.  Other research conducted on a genome-wide platform found that 26.7% of 
screen positive CNVs overlapped with the classic microdeletion/microduplication 
syndromes currently available on NIPS: 22q11.2 deletion/duplication, Prader-
Willi/Angelman syndromes, Cri-du-chat, and 1p36 deletion syndrome (Liang et al., 
2019).  Lo, Shiau, Chen, Shaw, and Benn (2019) reported an amniocentesis-confirmed 
case of 22q11.2 deletion syndrome with discordant results on NIPS.  NIPS via MPS 
rendered the fetus low risk, while NIPS via the SNP-based method indicated high risk 
with a 1/19 risk score.  While helpful, studies like these are not enough to change current 
recommendations.  There is continued work to be done to improve the sensitivity and 
PPV of these conditions to show that they are clinically validated for NIPS.   
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1.6.5 Twins or other multifetal gestations 
Data on NIPS in twin pregnancies are much more limited than in singleton 
pregnancies.  Understandably, the risk of aneuploidy increases with the number of 
fetuses; however, no method of screening works as well for twin pregnancies as it does 
for singleton pregnancies.  When NIPS is conducted in multifetal gestations, the 
laboratory report provides one result for the entire pregnancy, and therefore it is unclear 
which fetus(es) are indicating screen positive.  Gil et al. (2015) found detection rates 
similar to that of singleton pregnancies, but much more data are needed.  Until clinical 
validity can be demonstrated, screening multifetal gestations is not recommended by 
ACOG and ACMG at this time (ACOG, 2016; Gregg et al., 2016).  In instances when 
laboratories offer NIPS for multifetal gestations and the result is screen positive, 
diagnostic testing is essential in determining which fetus(es) are affected.  Not even SNP-
based platforms can make this distinction, though they can report on zygosity 
(monozygotic vs. dizygotic).   
1.7 Challenges of no call results 
 As is the case with screen positive NIPS results, there is a foundational challenge 
of no call results: follow-up protocol.  There are no consistent guidelines for managing 
this group of patients, leaving clinicians to make recommendations on a case-by-case 
basis.  Though some laboratories have begun supplying reasons for no calls beyond low 
fetal fraction, such as suspected maternal abnormality or laboratory error, most reports do 




 1.7.1 Low fetal fraction 
 Most commonly, however, NIPS fails to generate a result due to insufficient FF.  
Factors known to influence the FF include maternal weight, gestational age, maternal use 
of blood thinners, and aneuploidy.  Maternal weight and FF are inversely related, with 
increasing maternal weight leading to a decrease of FF.  Low FF can also occur if the 
gestational age at the time of the draw is earlier than the recommended 9-10 weeks of 
pregnancy, if the mother is taking blood thinners, or if the pregnancy is aneuploid.  When 
faced with an insufficient FF result, most laboratories accept a redraw.  The percentage of 
patients receiving a result after a second draw generally falls between 50-70% (Benn, 
Valenti, Shah, Martin & Demko, 2018; Galeva, Gil, Konstantinidou, Akolekar, & 
Nicolaides, 2019; Suzumori et al., 2019; White, Wang, Kunz, & Schmid, 2019).  
 Aneuploidy is the obvious area of interest for GCs considering low FF results, 
however.  One study found that in over 1,000 pregnancies, 8% of cfDNA screenings 
failed due to low FF.  Of those failures, 22% were determined to be aneuploid 
(Pergament et al., 2014).  Currently, a select laboratory categorizes low FF into high risk 
versus no result in attempt to decrease the number of patients receiving an overall no call.  
The high risk category is assigned when the laboratory’s internal algorithm suggests an 
increased risk for aneuploidy; this risk estimate is 1/17 for Triploidy, Trisomy 18, or 
Trisomy 13.  This result is generated when the low FF cannot be attributed to maternal 
weight, maternal age, and gestational age in addition to FF.  When a patient receives a 
high risk result based on this algorithm, prenatal diagnosis is the recommended follow-up 
as opposed to a redraw (Benn et al., 2019).  Because the implementation of this algorithm 
is fairly recent, reports of pregnancy outcomes are scarce.  
 11
1.7.2 Uninformative DNA pattern 
A newer type of no-call result is attributed to an uninformative DNA pattern.  
Because there are many possible explanations for uninformative results and limited data 
on these pregnancy outcomes, redraws are not recommended.    
1.7.3 Outcome data for no-calls 
Studies on pregnancy outcomes following no calls are limited.  Suzumori et al. 
(2019) evaluated outcomes of pregnancies receiving multiple no calls.  Of the 22 patients 
undergoing diagnostic testing after a second failure, 17 of those (77.2%) subsequently 
had a normal karyotype, while the remaining five (22.7%) were abnormal.  Interestingly, 
six of the 22 (27.2%) were twin pregnancies that had a low FF.  This is consistent with 
other literature that states twin gestations have a higher fail rate than singletons, with or 
without chromosome aneuploidy (Galeva et al., 2019).   
1.7.4 Novel explanations for no calls 
Because many no calls go without explanation, research into other possible causes 
is ongoing.  Putra et al. (2019) established a correlation between maternal 
hemoglobinopathies and no calls.  They found that women with clinically significant 
hemoglobinopathies were more likely to have low FF and subsequent no calls.  
Additionally, Suzumori and colleagues (2019) described increasing maternal age and 
certain racial origins as correlations with test failure.  Though these studies are helpful, it 
is reasonable to consider that there are other factors influencing the success of a NIPS 




1.8 Differences in laboratories’ reporting 
 In addition to challenges unique to positive and no call results, there are also 
aspects of laboratories’ reporting that can complicate interpretation of results.  For 
instance, it is recommended by the ACMG that detection rate, specificity, PPV, negative 
predictive value (NPV), and FF be included on each report for autosomal aneuploidies, 
sex chromosome aneuploidies, and CNVs (Gregg et al., 2016).  However, recent 
evaluation by Skotko et al. (2019) found that laboratories’ adherence is variable.  None of 
the ten laboratories analyzed fully met this requirement, and many did not distinguish 
PPV and NPV between conditions, especially the sex chromosome aneuploidies.  PPV is 
the statistic that patients are generally most concerned with, as it is the number that 
informs them the chance that the positive result is indeed true.  Counseling on a PPV that 
is nonspecific to the condition and is population-derived versus patient-specific is a 
significant hurdle in helping patients assess their actual risk; they may feel they are 
working with incomplete or conflicting information that is not specific to their 
pregnancies.  Skotko and colleagues (2019) found that only one laboratory consistently 
reported patient-specific PPV, or population-derived or modeled PPV only when patient 
clinical information was unavailable for calculation.   
 Furthermore, it is challenging when the data source for laboratories’ statistics is 
variable.  For example, laboratories may be reporting based on population studies, 
clinical studies, their own internal data, or in the case of one particular laboratory, their 
self-designed algorithm.  The lack of consistency indicates that a woman undergoing 
screenings with two laboratories at the same time could receive different results, and this 
is problematic for true risk assessment.  On the positive, however, the recent analysis of 
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Skotko and colleagues (2019) found that laboratories are evolving in their reporting of no 
call results.  Select laboratories are becoming more specific and supplying reasons for no 
calls beyond low fetal fraction and uninformative DNA pattern.  Classifications recently 
observed include triploidy, vanishing twin, or unrecognized multiple gestation; suspected 
maternal abnormalities; and sample processing/laboratory error.  A select laboratory is 
also distinguishing between maternal or fetal abnormalities in some of its reports, and this 
is very helpful for post-test counseling and management.   
1.9 Importance of clear results in screening 
 Prenatal screening is not a eugenics movement, though this perception is still held 
by many (Farrell et al., 2019).  While some patients certainly use screening as a guide for 
pregnancy management, others simply wish to be prepared for the potential of having a 
child with complex medical and developmental needs.  Nov-Klaiman, Raz, and Dolev 
(2019) identified parents of children with Trisomy 21 as being favorable toward NIPS, 
citing its accuracy, safety, and ability to help families prepare for a child with special 
needs.  Similarly, 88.1% of parents of children with SCAs reported that early diagnosis 
via NIPS was positively impactful (Samango-Sprouse et al., 2019).   
Other research has indicated that patients value actionability as a primary 
consideration of their personal utility for screening (Farrell et al., 2019).  Though not 
equivalent to diagnostic testing, it is clear that many women view NIPS as a suitable 
alternative; they are reassured with low risk results, and certainly concerned with high 
risk or inconclusive ones.  Therefore, it is extremely important that these screens are 
accurately reported and have clear guidelines for follow-up.  Providers hope for the same 
things, as they are the ones sought for guidance and management.  Richardson, Raine-
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Fenning, Deb, Campbell, and Vedhara (2017) found that an uncertain diagnosis was more 
distressing to patients psychologically than a diagnosis with a poor outcome.  Though this 
is always patient-dependent, there is enough research to show that uncertain results delay 
a diagnosis, complicate follow-up, and increase both patient and provider anxiety 
(Hancock et al., 2019).   
1.10 Rationale 
Little research has been conducted to assess the pregnancy outcomes of those 
receiving an abnormal NIPS, particularly those resulting in a no call.  Because the general 
uptake of NIPS is increasing, many abnormal results are generated.  Our practice will 
benefit from any associations gleaned during the course of this study.  The ultimate goal 




We predict that many pregnancy outcomes of low fetal fraction NIPS results will 
be normal, and they can likely be attributed to maternal weight or drawing blood at an 
early gestational age.  Similarly, many pregnancy outcomes of uninformative DNA 
pattern results will likely also be normal.  However, we do expect to observe novel 
correlations between uninformative DNA pattern results and pregnancy outcomes, since 
no call results outside of low fetal fraction are poorly understood.   
Objectives 
 
1) Observe positive predictive values of our patients’ NIPS results, and compare 
with the positive predictive values given by the performing laboratory. 
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2) Compare next steps (such as the uptake of prenatal diagnostic or postnatal 
testing) based on the type of condition indicated on NIPS. 
3) Establish novel correlations between no call results and pregnancy outcomes.  
4) Confirm known correlations such as maternal weight and early gestational 
age with low fetal fraction results, and observe any factors that are not as strongly 
correlated.  




















EVALUATING PREGNANCY OUTCOMES OF ABNORMAL NON-INVASIVE 

















1 Kesler, O., Fairey, J., Campbell, B., & Surka, W. To be submitted to American Journal 
of Obstetrics and Gynecology 
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2.1 Abstract 
Non-invasive prenatal screening (NIPS) has rapidly grown in uptake since its 
introduction to clinical practice in 2011.  In contrast to more traditional methods of 
screening, NIPS is the first to utilize cell-free fetal DNA for risk assessment of 
chromosomal aneuploidy and other conditions.  Clinical validity has been established for 
the most common autosomal aneuploidies (Trisomy 21, Trisomy 18, and Trisomy 13) 
and sex chromosome aneuploidies, though some laboratories screen for conditions 
beyond these.  A screen positive does not always indicate a true positive, therefore 
professional guidelines recommend diagnostic testing for confirmation and informed 
decision making on pregnancy management.  Furthermore, the methodology of NIPS 
means a positive result could be maternal or placental in origin and not necessarily 
represent the fetus.  It is also possible to get a no call result that could suggest another 
genetic aberration, at which point patients and providers are left to follow up at their own 
discretion due to the lack of management guidelines.  The goal of our study was to track 
pregnancy outcomes for patients receiving abnormal NIPS results, and use those 
outcomes to develop follow-up protocol for our practice.  Additionally, we sought to 
make novel correlations for no call results.  One hundred eighty one women were eligible 
for inclusion after medical record review.  Consistent with other research, the greatest 
number of true positives were for autosomal aneuploidies.  Patients’ uptake of diagnostic 
testing was impacted by the individual result type, presence of ultrasound abnormalities, 
and laboratories’ indications of a maternal or fetal abnormality.  During the course of our 
study, some laboratories began specifying reasons for no calls.  This was helpful in 
guiding management, as certain types of no calls were more strongly associated with 
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abnormalities and/or adverse fetal outcomes.  Several no call results in our study led to 
the identification of genetic aberrations in both fetuses and mothers, suggesting the 
importance of follow-up and appropriate management.  Overall, our study reiterates the 
importance of diagnostic testing as confirmation for screen positives, contributes 
outcome data to the growing incidence of abnormal NIPS results, and provides follow-up 
recommendations based on each result type. 
2.2 Introduction 
 Though originally introduced as screening preferred for the high-risk population, 
NIPS has rapidly expanded in use and is now often the first choice over traditional 
screening methods.  Because the uptake has dramatically increased, more women are 
faced with an abnormal result, either positive or no call.  Current professional guidelines 
are not in agreement with recommendations for follow-up, and some results are not even 
addressed in these guidelines (ACOG, 2016; Gregg et al., 2016).  
 Because a screen positive result may not be representative of the fetus, diagnostic 
testing remains the standard recommended follow-up for all results.  In some scenarios 
such as low fetal fraction (LFF), however, a redraw may be successful (Suzumori et al., 
2019).  Coverage of NIPS platforms has rapidly expanded, though professional 
guidelines have not been updated to reflect this.  Currently, it is recommended to screen 
only for the three most common autosomal trisomies as well as sex chromosome 
aneuploidies (SCAs).  Recommended follow-up for screen positive autosomal trisomies 
is always diagnostic testing and ultrasonography (ACOG, 2016; Gregg et al., 2016).  In 
SCAs, however, follow-up guidelines are less consistent.  While diagnostic testing is 
usually the most informative, providers have to also consider the chance that the positive 
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result represents a maternal sex chromosome difference, such as mosaic Monosomy X or 
XXX syndrome (Fleddermann et al., 2019).  SCAs are also difficult to corroborate with 
ultrasound findings, which can often be done in the setting of a screen positive autosomal 
trisomy.  As a result, these conditions approved by professional societies for inclusion on 
NIPS are without follow-up recommendations.  For those conditions that professional 
societies consider invalid due to low prevalence and PPV, follow-up recommendations 
are not uniformly available; therefore, pregnancy management of a screen positive patient 
is left to the discretion of the provider.   
 In regard to no calls, the most common type is due to LFF.  Sometimes, a LFF 
result can be correlated with risk factors such as high maternal weight, early gestational 
age, maternal use of blood thinners, and aneuploidy (Galeva, Gil, Konstantinidou, 
Akolekar, & Nicolaides, 2019).  While redraws are often accepted, it is not a perfect 
solution.  The percentage of patients receiving a result after a second draw generally falls 
between 50-70% (Benn, Valenti, Shah, Martin & Demko, 2018; Galeva et al., 2019; 
Suzumori et al., 2019; White, Wang, Kunz, & Schmid, 2019).  In the setting of a failed 
redraw, it may not always be clear why screening has been unsuccessful.  One laboratory 
is trying to address this with a new type of LFF result.  When LFF cannot be attributed to 
maternal weight, maternal age, or gestational age, a 1/17 risk for Triploidy, Trisomy 13, 
or Trisomy 18 is suggested (Benn et al, 2019).  For this type of result, the laboratory 
recommends diagnostic testing instead of a redraw.  Similarly, several other types of no 
calls have recently been reported, such as maternal X abnormalities or atypical findings.  
When laboratories are able to make the distinction between a maternal or fetal 
abnormality, this allows genetic counselors (GCs) to recommend the most appropriate 
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follow-up to learn more about the abnormal result; however, it should be noted that 
learning of this distinction often requires a GC to call the laboratory directly for more 
information.  Differences in maternal and fetal abnormalities are not always readily 
available on the laboratory report.  Uninformative DNA pattern (UDP) results have also 
become more common, though the laboratory does not encourage sending a redraw.  
With many possible reasons for a UDP result and no guidelines for follow-up, next steps 
can look very different from patient to patient based on her own choice and discretion.   
 Many women rely on NIPS for accurate risk assessment of their pregnancies.  
They are reassured by low risk results, and certainly concerned by abnormal ones.  
Therefore, it is extremely important that these screens perform well, and equally 
important that laboratories and professional guidelines equip providers to recommend the 
most appropriate follow-up and management.  Because each laboratory has different 
ways of reporting results and varying factors that contribute to their results, it is 
sometimes difficult for providers to decide how real or how worrisome an abnormal 
result should be.  Therefore, we seek to provide valuable outcome data for both 
established and evolving types of results on NIPS platforms.   
2.3 Materials and Methods 
 2.3.1 Participants 
Participant selection was based on record review.  Eligible participants were 
patients of Prisma Health-University of South Carolina Maternal Fetal Medicine (MFM) 
or Prisma Health-Greenville MFM that had an abnormal NIPS documented in their 
electronic medical record (EMR).  Patients seen between January 2018 – March 2020 
were eligible for inclusion.  A total of 181 patients met these requirements.  Demographic 
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characteristics of the participants are summarized in Table 2.1.  The population consisted 
of mostly Caucasian (45.3%, n=82) and African American (43.6%, n=79) individuals.  
All participants were female with a mean age of 31.4 years.  The average gestational age 
at which NIPS was drawn was 13.6 weeks.  Average maternal weight was 185.9 pounds.   
Table 2.1 Demographic characteristics of participants 
Characteristics n % 
Age (n=181)   
      16-20 17 9.4 
      21-25 27 14.9 
      26-30 43 23.8 
      31-35 34 18.8 
      36-40 38 21.0 
      41-45 22 12.1 
Ethnicity (n=181)   
      Caucasian 82 45.3 
      African American 79 43.6 
      Hispanic/Latino 13 7.2 
      Asian 2 1.1 
      Multiethnic 5 2.8 
Gestational age (n=181)   
       9-13  126 69.6 
      14-18 34 18.2 
      19-23 12 6.6 
      24-28 8 4.4 
      29-33 1 0.55 
      34-38 1 0.55 
Gestation (n=181)   
      Singleton 173 95.6 
      Twin 8 4.4 
Gravidy (n=181)   
      Primigravida 35 19.3 
      Multigravida 146 80.7 
Weight (n=177)   
      100-179 94 53.1 
      180-259 64 36.2 
      260-339 17 9.6 
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      340-419 1 0.55 
      420-499 1 0.55 
  
2.3.2 Procedure 
EMRs were reviewed to determine the eligibility of patients.  Once eligibility was 
determined, a unique identifier was assigned to each patient based on where she was seen 
(PH-USC for Prisma Health University of South Carolina MFM or PH-G for Prisma 
Health Greenville MFM).  A number of data points were extracted from each patient’s 
record: name; medical record number; address; phone number; age at delivery; weight; 
ethnicity; heparin/lovenox use (yes or no); gravidy and parity; gestational age; singleton 
or twin gestation; ultrasound findings; platform used for screening; was this repeat 
screening (yes or no); fetal fraction on laboratory report; the result- positive or no-call; if 
positive, what condition and the PPV; predicted fetal sex; follow-up plan (diagnostic 
testing or further ultrasounds); outcome (confirmed by diagnosis, clinical notes, or test 
results); and other (relevant maternal/placental conditions).   
 The goal was to document a pregnancy outcome for each abnormal result.  This 
may have been accomplished through diagnostic testing or postnatal testing that was 
documented in the EMR.  If patients did not have this information available in their 
record, they were sent a letter regarding a planned phone interview with the ability to opt 
out (Appendix A).  When patients were called, they were only asked about their 
pregnancy outcomes.  A total of 25 patients were sent a letter, and we were able to glean 
12 outcomes from phone interviews.  Another 12 patients could not be reached or did not 
return our phone call, and one patient declined to participate.  None of the patients 
contacted for a phone interview were 18 years old or younger.   
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 We utilized both qualitative and quantitative data analysis for our study.  Analysis 
was performed from January 2020 to March 2020.  Descriptive statistics were conducted 
for all 13 result types that were a part of our study.  Quantitative data analysis was 
performed using SPSS statistical analysis software and Microsoft Excel.   
2.4 Results 
   Information on all 181 patients was considered in reporting results and 
calculating statistics.  A screen positive Trisomy 21 was the most common (27.1%, 
n=49), followed by Monosomy X (12.7%, n=23).  Screen positives are outlined in Figure 
2.1, and outcomes are classified in Figure 2.2.  All results and outcomes are detailed in 
Table 2.2, and are further delineated by laboratory in Appendix B.   
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Figure 2.2 Outcomes for all pregnancies 













Trisomy 21 41 2 3 3 0 49 
Trisomy 18 10 3 5 0 0 18 
Trisomy 13 4 3 1 2 0 10 
Monosomy X 3 6 8 6 0 23 
XXY 1 2 1 0 0 4 
XYY 0 0 0 2 0 2 
XXX 0 0 0 2 0 2 




4 28 0 8 0 40 
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2.4.1 Trisomy 21  
 
 A total of 49 patients were screen positive for Trisomy 21 (T21) (27.1%).  Results 
were generated by eight different laboratories.  The average maternal age of patients was 
33.6 years, and the average gestational age was 13.0 weeks.  Most were multigravida 
(86%, n=43) and advanced maternal age (AMA) (54%, n=27).  The average PPV 
provided by laboratory reports was 81.1% (n=44).  One screen positive occurred in a twin 
gestation (2%).  Ultrasound abnormalities were detected in 65.3% (n=32).  The majority 
were confirmed as true positives (83.7%, n=41).  Outcomes for all screen positives are 
classified in Figure 2.3.  Most patients declined diagnostic testing (55.1%, n=27).  
Decision-making for screen positives is outlined in Figure 2.4 
 Considering only true positives, the majority of women were AMA (58.5%, 
n=24).  Most cases were diagnosed prenatally (51.2%, n=21), while the remaining 20 
were postnatally confirmed (48.8%).  One true positive was a partial duplication of 
chromosome 21, but the rest were full aneuploidy.  One true positive was Twin A in a 
dichorionic/diamniotic gestation.  Most affected pregnancies demonstrated ultrasound 
abnormalities, which are detailed in Appendix C (75.6%, n=31).  Affected pregnancies 






























2.4.2 Trisomy 18 
A total of 18 patients were screen positive for Trisomy 18 (T18) (9.9%).  The 
average maternal age of participants was 35.3 years, and the average gestational age was 
12.2 weeks.  Most were multigravida (77.8%, n=14) and AMA (66.7%, n=12).  The 
average PPV provided by laboratory reports was 59.04% (n=16).  The majority were 
confirmed as true positives (55.5%, n=10).  Outcomes for all screen positives are 
classified in Figure 2.5.  Most patients with a screen positive opted to proceed with 
diagnostic testing (55.5%, n=10), with the majority having ultrasound abnormalities 
(70%, n=7).  Decision-making for screen positives is outlined in Figure 2.6.  
 Considering only true positives, the majority of women were AMA (80%, n=8).  
Most cases were diagnosed prenatally via amniocentesis (70%, n=7), while the rest were 
postnatally confirmed (30%, n=3).  One case was mosaic T18, while the others were full 
aneuploidy.  Most affected pregnancies demonstrated ultrasound abnormalities, which are 



























2.4.3 Trisomy 13 
Ten patients were screen positive for Trisomy 13 (T13) (5.5%).  The average 
maternal age of participants was 26.8 years, and the average gestational age was 15.3 
weeks.  Most were multigravida (80%, n=8), yet only one was AMA (10%).  The average 
PPV provided by laboratory reports was 26.03% (n=7).  Four were confirmed as true 
positives (40%).  Outcomes for all screen positives are classified in Figure 2.7.  Three 
patients opted to proceed with diagnostic testing (30%).  Decision-making for screen 
positives is outlined in Figure 2.8.   
 Considering only true positives, the majority of women were not AMA (75%, 
n=3).  Most cases were diagnosed prenatally (75%, n=3), while the remaining case was 
postnatally confirmed.  One case was mosaic T13, while the others were full aneuploidy.  
Half of affected pregnancies demonstrated ultrasound abnormalities, which are detailed 
in Appendix E (50%, n=2).  Affected pregnancies were majority male (75%, n=3).   
 











Figure 2.8 Decision-making for T13 screen positives 
 2.4.4 Monosomy X 
A total of 23 patients were screen positive for Monosomy X (12.7%).  The 
average maternal age of participants was 28.04 years, and the average gestational age was 
11.7 weeks.  Most were multigravida (73.9%, n=17) and below AMA (82.6%, n=19).  
The average PPV provided by laboratory reports was 24.9% (n=17).  Three were 
confirmed as true positives (13%).  Outcomes for all screen positives are classified in 
Figure 2.9.  Six patients opted to proceed with diagnostic testing (26%).  Decision-
making for screen positives is outlined in Figure 2.10.   
 Considering only true positives, the average maternal age was 22.7 years.  Two 
cases were diagnosed prenatally (66.7%, n=2), while the remaining case was confirmed 
via studies on products of conception.  All affected pregnancies demonstrated ultrasound 








Figure 2.9 Outcomes for Monosomy X screen positives 
 
















 2.4.5 XXY 
 Four patients received a positive result for XXY, or Klinefelter syndrome (2.2%).  
The average maternal age of participants was 32.3 years, and the average gestational age 
was 11.0 weeks.  Three of the four patients were multigravida (75%).  The average PPV 
provided by laboratory reports was 64% (n=4).  One case was a true positive (25%).  
Outcomes for all screen positives are classified in Figure 2.11.  Half of patients opted for 
diagnostic testing (50%, n=2).  Decision-making for screen positives is outlined in Figure 
2.12.  
Considering the only true positive case, the patient was 30 years old and she 
received the diagnosis via amniocentesis.  The fetus demonstrated no abnormalities.  
 










Figure 2.12 Decision-making for XXY screen positives 
 2.4.6 XYY 
Two patients received a positive result for XYY (1.1%).  The average maternal 
age of participants was 24.5 years, and the average gestational age was 12.0 weeks.  Both 
patients were multigravida (100%).  Results were generated by two different laboratories; 
one patient was given an 89% PPV while the other was not listed on the report.  The 
patients had no ultrasound abnormalities, nor did they opt for diagnostic testing.  One 
patient was lost to follow-up regarding postnatal testing, and the other had declined 
diagnostic testing and was still pregnant by the completion of our study.   
 2.4.7 XXX 
We had two screen positive results for XXX syndrome (1.1%).  The average 
maternal age was 39.0 years, and the average gestational age was 11.5 weeks.  Both 
reports were generated by the same laboratory with a PPV of 38%.  Both patients were 






for maternal chromosome analysis, but it was ultimately normal.  Neither patient 
demonstrated ultrasound abnormalities, nor did they opt for diagnostic testing.  One 
patient could not be reached for follow-up, and another patient declined postnatal testing.  
As such, no outcome data are available.   
 2.4.8 Microdeletions 
 A total of three patients were screen positive for microdeletions, all 22q11.2 
deletion syndrome (1.7%).  One patient’s report noted a suspected maternal finding.  The 
average maternal age of patients was 22.6 years, and the average gestational age was 11.3 
weeks.  The average PPV provided by laboratory reports was 20% (n=2).  Outcomes for 
screen positives are classified in Figure 2.13.   
 Considering only true positives, the average maternal age was 21.5 years (n=2).  
Both fetuses demonstrated Tetralogy of Fallot (TOF) on ultrasound.  Both patients 
declined diagnostic testing and instead opted for postnatal confirmation.   
There was one male and one female affected (n=2).  The patient whose report noted a 
suspected maternal finding underwent chromosomal microarray (CMA), which 
confirmed the presence of a pathogenic 22q11.2 deletion.  She did not opt for prenatal 
diagnosis.   
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Figure 2.13 Outcomes for microdeletions 
 
 2.4.9 No call- low fetal fraction 
 A total of 21 patients had a general no call- LFF result (11.6%).  The average 
maternal age was 31.6 years, and the average gestational age was 14.5 weeks.  Of 
provided fetal fractions, the average was 3.3 (n=12).  The average maternal weight was 
263.4 pounds, with the majority weighing over 240 pounds (57.1%, n=12).  Maternal 
weights are graphed in Figure 2.14.  Several associations of LFF results were noted in our 
patients, and these are outlined in Figure 2.15.  A greater proportion of patients carrying 
singletons as opposed to twins were over 240 pounds (71.4%, n=10).   
 The majority of patients attempted a redraw (62%, n=13).  Decision-making for 
the results are summarized in Figure 2.16.  Patients receiving an informative redraw 
weighed slightly less (267.2 pounds) than patients receiving a second no call (275.1 
pounds), however, this was not statistically significant, t(11) = 0.16, p = .88.  They also 







comorbidities had unsuccessful redraws.  No genetic aberrations were confirmed among 
patients for whom outcome data were available (81%, n=17), though one patient with two 
LFF results and abnormalities was lost to follow-up, and another reported her that child 
was born with a heart defect.  These cases are detailed in Table 2.3.   
 














Figure 2.15 Attributes noted in patients with LFF results 
 
 































































2.4.10 High risk for triploidy, trisomy 18, or trisomy 13 due to LFF 
A total of 19 patients were high risk for Triploidy, T18, or T13 due to LFF 
(10.5%).  This is a specific type of LFF result unique to Natera, and it is generated when 
LFF cannot be attributed to maternal age, gestational age, or maternal weight.  Results 
are not given for other chromosomes, including the sex chromosomes.  The average 
maternal age was 29.8 years, and the average gestational age was 14.3 weeks.  Average 
maternal weight was 196.7 pounds.  The difference in maternal weight from those with 
general LFF results was statistically significant, t(38) = 3.1, p = .004.  Most were 
multigravida (84.2%, n=16) but not AMA (78.9%, n=15).  The risk estimate for this 
result is 1/17 (5.9%), therefore all patients received the same PPV.  Three were 
confirmed as true positives (15.8%).  Outcomes for this result type are classified in 
Figure 2.17.  Three patients opted for diagnostic testing (15.8%).  Decision-making in 
this result type is outlined in Figure 2.18.  
 Considering only true positives, all three women were below AMA.  Two cases 
were confirmed as T18 (66.7%), and the other was triploidy (33.3%).  One case of T18 
was diagnosed prenatally via amniocentesis (33.3%), while the other was postnatally 
confirmed.  The case of triploidy was confirmed via postnatal studies after the patient had 
an IUFD at 17 weeks.  All three affected pregnancies demonstrated ultrasound 













































Figure 2.18 Decision-making for high risk for Triploidy, T18, or T13 due to LFF results 
High risk for 
Triploidy, T18, or T13 








































2.4.11 No call- uninformative DNA pattern 
A total of 10 patients received a no call UDP result (5.5%).  This no call type is 
unique to Natera.  Two of these patients (20%) received two UDP results.  The average 
maternal age of participants was 30.1 years, and the average gestational age was 14.4 
weeks.  Three (30%) genetic findings across four abnormal outcomes were identified: 
maternal XXX mosaicism, consanguinity, and two variants of uncertain significance 
(VUS) in one patient.  Outcomes for this result type are classified in Figure 2.19.  Most 
patients with a screen positive declined diagnostic testing (60%, n=6).  Decision-making 
for this result type is outlined in Figure 2.20.  
 
 

































































Variants in FANCD2 











2.4.12 No call- triploidy, vanishing twin, or unrecognized multiple gestation 
 We had a total of five patients that received a result for triploidy, vanishing twin, 
or an unrecognized multiple gestation (2.8%).  This is a result unique to Natera, and it is 
generated when three DNA patterns are identified, but cannot be delineated based on 
origin.  Typical risk assessment for aneuploidy cannot be run due to the unknown 
etiology of the third DNA contribution.  The average maternal age was 27.4 years, and 
the average gestational age was 16.2 weeks.  Two patients had identifiable outcomes 
consistent with this call, resulting in an overall PPV of 40%.  Outcomes for this result 
type are classified in Figure 2.21. 
Considering only true positives, the average maternal age was 30.5 years.  Neither 
patient opted for diagnostic testing, as their ultrasounds revealed the likely reason for 
their abnormal screens: molar pregnancy and twin pregnancy.   
 















2.4.13 Other results 
 Fifteen patients received atypical findings including double screen positive results 
or another type of no call (8.3%).  These results are summarized in Table 2.4.  The 
average maternal age was 33.3 years, and the average gestational age was 12.7 weeks.  
Average maternal weight was 191.3 pounds.  Most were multigravida (73.3%, n=11) and 
not AMA (66.7%, n=10).  No fetal diagnoses were made, however, three maternal ones 
were confirmed: one mosaic Monosomy X, one 13q microdeletion, and one Xq;3q 
unbalanced translocation.  Outcomes for these results are outlined in Figure 2.22.  Only 
one patient with a screen positive opted for diagnostic testing of her fetus (6.7%), 
however, three patients chose chromosome analysis for themselves (20%).  Decision-
making for these results is highlighted in Figure 2.23.   
Three patients had exactly the same abnormal results (20%).  They each received 
a no call- LFF result from Natera followed by a high risk for Triploidy, T18, or T13 
result on redraw before having assumed normal fetal outcomes.  Knowing that FF is 
important for both of these result types, we calculated the means of factors known to be 
associated with LFF.  Results are shown in Table 2.5.  The average maternal weight falls 




Table 2.4 All results for other (multiple aneuploidies or abnormal results) 
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Table 2.5 Average age, weight, and GA in those receiving both general LFF and high 
risk LFF results  
 PH-USC 58 PH-USC 60 PH-G 31 Means 
Maternal age 29 30 30 29.7 years 
Maternal 
weight 
180 236 301 239 pounds 
GA at first 
draw 




Outcome data for pregnancies with abnormal NIPS are few, and most available 
literature has been generated by laboratories featuring their own data.  Our study 
contributes outcome data for abnormal screening results across several laboratories and 
platforms.  This is particularly important given that new result types are quickly evolving 
before professional guidelines can develop follow-up recommendations.  Additionally, 
follow-up recommendations for conditions established on NIPS, such as SCAs, are 
inconsistent (Fleddermann et al., 2019).  Importantly, we were able to develop 
management guidelines for our practice based on the various no call or 
atypical/uninformative result types, as seen in Figure 3.1.  Recommended follow-up for 
any high risk result remains diagnostic testing, including karyotype and CMA.  The 
importance of conducting both chromosome analyses was reinforced by two cases of 
mosaicism and one case of a partial chromosome duplication.  Serial growth ultrasounds 
should be offered to those declining diagnostic testing in order to monitor for 
complications of intrauterine growth restriction (IUGR).  Patients with unexplained LFF 
also benefit from serial growth ultrasounds, similar to how patients with unexplained 
elevations in AFP (alpha-fetoprotein) are managed.  This is not only because the chance 
of aneuploidy remains without diagnostic testing to confirm or rule it out, but also that 
LFF could be due to a placental issue which would place a risk of growth restriction on 
the fetus.  We also included a step to contact a GC at the performing laboratory for 
uninformative/atypical result types; in several cases, we were able to learn more about 
chromosomes of interest and whether or not the abnormality appeared to be maternal or 
fetal in origin when this information was not included on the report.  Obtaining this 
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information from the laboratory GCs was valuable in guiding management, and it led to 
several patients pursuing their own chromosome studies when otherwise there would 
have likely been no follow-up.   
We observed several patterns in our data that are in agreement with background 
research.  Uptake of diagnostic testing was highest in the autosomal trisomies despite 
there not being full consistency between conditions (Figure 3.2) (Gil, Quezada, Revello, 
Akolekar, & Nicolaides, 2015.)  Most patients with a screen positive T18 opted for 
diagnostic testing in the presence of ultrasound abnormalities, while most of those opting 
for diagnostic testing in T21 or T13 did so in the absence of abnormalities (Figure 3.3).  
There were cases that reinforced the importance of diagnostic testing to confirm or rule 
out an abnormal result, as several fetuses with ultrasound findings ultimately had normal 
karyotypes, therefore ruling out the screen positive (Table 3.1).  Patients and providers 
may factor ultrasound findings into risk assessment when diagnostic testing is declined, 
however, it is extremely important to confirm a diagnosis for appropriate medical 
management and before irreversible pregnancy management decisions are made.   
Unsurprisingly, we saw lower uptake of diagnostic testing in SCAs.  This is likely 
due to the lack of medical complications and generally mild phenotypes associated with 
these conditions.  There was a high rate of IUFD among those with screen positive 
Monosomy X, which is consistent with reports in the literature (Suzumori & Sugiura-
Ogasawara, 2010).  In combination with what is known about phenotypes of SCAs, 
patients likely declined diagnostic testing knowing the rate of miscarriage for true 
positives is high.  Similarly, uptake of diagnostic testing was low for microdeletions and 
various types of no calls.  One exception to this was for uninformative DNA pattern 
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results.  We saw higher uptake of diagnostic testing compared to other no call results, but 
also an increased number of abnormalities, adverse fetal outcomes, and repeat screening 
failures.  The specificity of this result suggesting an abnormality in the DNA may have 
impacted decision-making among patients.  As a result, diagnostic testing (karyotype and 
CMA) was the most informative next step for this result type, including maternal 
karyotype and CMA, as we were able to make one maternal diagnosis after she received 
this result.   
Interestingly, we saw reasonable success in redraws for result types that 
laboratories do not necessarily recommend, namely high risk for Triploidy, T18, or T13 
due to LFF (Benn et al., 2019).  Though Natera advises diagnostic testing as the next step 
for this result, the redraw success rate suggests that a second attempt may render the fetus 
low risk for conditions within the scope of the laboratory’s screening platform (common 
trisomies and SCAs).  On the contrary, we also observed several repeat failures in LFF 
results.  For reasons unknown, several women with assumed normal fetal outcomes could 
not get a successful result even when they were of appropriate gestational age and weight 
with no other risk factors.  It is possible that these low FF results were due to a genetic 
aberration outside the scope of the screening test, again underscoring the importance of 
diagnostic testing.  Placental abnormalities could also be the explanation, further 
highlighting the importance of patients following-up with growth ultrasounds throughout 
the duration of their pregnancies. 
In several cases, there was indication to offer maternal testing.  As a result, we 
observed five maternal diagnoses (Table 3.2).  In addition to 22q and 13q deletions, X 
chromosome abnormalities for three mothers were identified by three different Natera 
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result types.  This suggests that while there may have been high accuracy in these calls, 
consistency between result types and what they are indicating needs to be further 
developed.  Similarly, we saw the impact of laboratories specifically indicating maternal 
differences on their reports or providing this information to GCs when they called the 
laboratory.  Uptake of maternal chromosome analysis was high when this distinction was 
made.  
Several new types of no call results evolved over the course of our study.  We 
observed several patients with double screen positive results, as well as results suggestive 
of maternal abnormalities.  When a maternal distinction was made, patients were more 
likely to opt for their own chromosome analysis.  With one abnormal result citing a 
general atypical finding, we were able to get more specific information by calling the 
laboratory.  A laboratory GC is often able to provide information on the raw data that 
may be helpful in counseling patients in follow-up and management.   
 2.5.1 Trisomy 21 
T21 was our most frequent screen positive, which is not surprising given that it 
has the highest incidence of all conditions screened (27.1%, n=49).  Diagnostic testing 
was mostly declined, likely because of the procedural risks and the fact that it would not 
impact pregnancy management.  We also had a high frequency of abnormalities in this 
result type; interestingly, the ones that pursued diagnostic testing did so largely in the 
absence of abnormalities, suggesting that it may have been an important factor in patients 
choosing follow-up.  Two patients chose maternal serum screening (MSS) as their next 
step, and both were abnormal for T21.  As they did not follow-up with diagnostic testing 
after the second abnormal screen, it is likely they used this information as soft 
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confirmation until postnatal testing could confirm the diagnosis.  This is consistent with 
previous literature that states patients may use abnormalities, concurrent MSS, or other 
factors as corroborating evidence for screen positive NIPS results, and therefore feel 
justified in not pursuing prenatal diagnosis (Zhen, Li, Yang, & Li, 2019).   
 The number of affected pregnancies showing ultrasound abnormalities was 
slightly higher than expected at 75.6%, given that most estimates hover around 50% 
(ACOG, 2016).  This could be because our patients received targeted ultrasounds by high 
risk specialists.  Additionally, many of them were scanned more than once which 
provided a larger timeframe for identification of abnormalities.   
 The unique circumstances of two cases further emphasized the importance of 
diagnostic testing and complete chromosome analysis.  One screen positive was part of a 
dichorionic/diamniotic twin gestation.  The laboratory could not identify which twin was 
indicating screen positive, however, multiple abnormalities in Twin A provided 
suspicion.  Regardless of the presence of abnormalities, diagnostic testing was the only 
way to determine which, if any, twin had T21, as only one result is given for the entire 
pregnancy.  Similarly, one true positive case was a partial chromosome 21 duplication.  
Partial aberrations versus full aneuploidy is an important distinction that can only be 
made by completing both karyotype and microarray.    
 The outcomes for three patients could not be classified.  PH-USC 40 agreed to a 
follow-up phone interview after the outcome of her pregnancy was not documented in the 
EMR.  She previously had a normal anatomy scan and declined diagnostic testing.  At the 
time of the interview, she stated that her daughter did not have T21, but that two heart 
defects were identified upon her birth.  She reported that genetic testing had not been 
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performed due to her daughter’s lack of facial features typical of someone with T21.  We 
could not classify her outcome without confirmatory testing, however, mosaic trisomy 21 
could be a possible explanation.  Perhaps the most interesting case, however, is PH-USC 
89.  Her history included one prior SAB at 12 weeks (G1), and a second pregnancy that 
was screen positive for T21 on second trimester MSS.  That pregnancy (G2) ended in 
demise at 39 weeks with growth restriction and shortened femurs.  No postnatal testing 
was carried out to determine a diagnosis.  At the time of her positive NIPS in our practice 
(G3), she declined diagnostic testing but opted to have her chromosomes analyzed.  She 
returned a normal karyotype.  Likewise, her daughter (G3) returned a normal karyotype 
after delivery.  Her partner and father of all three pregnancies declined chromosome 
analysis.  It is possible that a maternal duplication on chromosome 21 too small for 
standard karyotype analysis is the explanation for this family.  This possibility further 
supports offering both karyotype and microarray in the setting of a positive NIPS, as 
results may be flagged for partial chromosome aberrations and not necessarily full 
aneuploidy.  The third patient, PH-USC 115, was lost to follow-up after normal imaging 
and 65% PPV.  
 2.5.2 Trisomy 18 
 T18 made up 9.9% of our abnormal results (n=18).  In contrast to those who were 
screen positive for T21, most opted for diagnostic testing, even though the majority did 
show ultrasound abnormalities.  This may be due to patients’ desire to discuss pregnancy 
management and/or surgical intervention options given the poor prognosis for this 
condition (Farrell, Agatisa, Michie, Greene, & Ford, 2019).  One patient chose MSS as 
her next step, and it was concordant with her abnormal NIPS result.  Similar to the T21 
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patients, she did not follow-up with diagnostic testing after the second abnormal screen, 
likely using that information as soft confirmation and justification for not pursuing 
prenatal diagnosis.   
The unique circumstances of two cases further emphasized the importance of 
diagnostic testing and complete chromosome analysis.  PH-USC 4 was a 38 year old who 
was screen positive with a 49% PPV.  At her anatomy scan, CPCs and an EIF were 
identified.  She opted for amniocentesis which subsequently revealed a normal female 
karyotype.  Her case reinforces that while ultrasound abnormalities can be used in risk 
assessment for a screen positive, diagnostic testing is essential for confirming or ruling it 
out.  Additionally, PH-USC 87 received a screen positive and had multiple ultrasound 
findings, however, karyotype revealed mosaicism as opposed to full aneuploidy.  
Mosaicism can complicate but also positively impact conversations surrounding 
prognosis and medical interventions; therefore, it is an important distinction to make. 
2.5.3 Trisomy 13 
T13 made up 5.5% of our abnormal results (n=10).  In contrast to those who were 
screen positive for T18, most declined diagnostic testing in the absence of ultrasound 
abnormalities.  This was an interesting difference given that the two conditions have 
almost equally poor prognoses.  A smaller proportion of affected pregnancies 
demonstrated abnormalities on ultrasound, though data may have been limited by only 
having first trimester imaging on two of the four patients.  An overall lower average PPV 
for this condition compared to T18 likely contributed to less uptake of diagnostic testing.  
PPV is an important statistic for most patients when discussing abnormal results; 
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therefore, a lower PPV in combination with a normal ultrasound likely provided 
reassurance to patients. 
The unique circumstances of two cases further emphasized the importance of 
diagnostic testing and complete chromosome analysis.  Patient PH-USC 6 showed renal 
pyelectasis on anatomy scan, however, this was not an overly suspicious finding given 
her 8% PPV.  Additionally, her anatomy scan was consistent with a male fetus, which 
was important to note given that pyelectasis is more common in males (Ebrashy et al., 
2016).  The fetal karyotype returned normal.  PH-USC 27 had a normal ultrasound when 
she opted for amniocentesis, understanding that the lack of ultrasound findings could not 
serve as reassurance for a false positive.  The karyotype subsequently returned mosaic for 
T13.  In this case, the revelation of mosaicism likely complicated the conversation 
regarding prognosis and medical management, but it was still an important distinction to 
make.   
2.5.4 Monosomy X 
Monosomy X made up 12.7% of our abnormal results (n=23).  Like those who 
were screen positive for T13, most declined diagnostic testing in the absence of 
ultrasound abnormalities.  Ultrasound abnormalities in SCAs as a whole are less reliable 
factors for risk assessment, however, the one true positive patient that declined prenatal 
diagnosis had multiple abnormalities, suggesting this may have impacted her decision.  
Additionally, there is a high rate of miscarriage in Monosomy X.  Knowing this statistic 
in combination with procedural risks for prenatal diagnosis may have deterred patients 
from pursuing this option.  Roughly a third of the screen positive pregnancies ended in 
demise between 11-22 weeks and did not have further testing.  All but one had either a 
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cystic hygroma or increased NT.  Given the abnormal screening results, abnormalities, 
and demises, these are suspicious for true positives, however, without confirmatory 
testing they could not officially be classified.   
While maternal mosaicism could be an explanation for at least a few of our false 
positive cases, none of the patients opted for maternal karyotype.  Only one of these 
patients had a history of pregnancy loss, however, this same patient also had three healthy 
pregnancies.   
2.5.5 XXY 
XXY, or Klinefelter syndrome, made up 2.2% of our abnormal results (n=4).  
Predictably, none of the four pregnancies demonstrated abnormalities.  Half of the 
patients opted for diagnostic testing, which demonstrated their understanding that the lack 
of ultrasound findings could not serve as reassurance for a false positive (Fleddermann et 
al., 2019).   
Two patients received PPVs from the same laboratory that were drastically higher 
than their risks on NSGC’s PPV calculator, though one was ultimately a true positive.  
Natera reports factoring age-related risk into their calculation of PPV, however, this 
discrepancy is a great limitation in post-test counseling and guiding patients through 
management and decision-making.   
Maternal mosaicism could be an explanation for our false positives, however, 







XYY syndrome made up 1.1% of our abnormal results (n=2).  Predictably, neither 
of the two pregnancies demonstrated abnormalities.  They also declined diagnostic 
testing, possibly due to the reported mild phenotype associated with this condition.  
Only one patient received a PPV (89%) on her laboratory report (Natera).  As was 
the case in two XXY results, this number is drastically higher than her risk on NSGC’s 
PPV calculator, 25%.  It is difficult to counsel knowing this discrepancy exists.  
Similarly, it is difficult to counsel when no PPV is provided by the laboratory.  This is a 
valuable statistic used by both providers and patients to answer the question, “How 
worried should I be?”  Without other factors to consider in these types of conditions (i.e. 
ultrasound findings), it leaves patients limited to diagnostic testing as their option to 
further clarify the result.  While always the most informative option, it is often selected 
against in our population. 
2.5.7 XXX 
We had two screen positive results for XXX syndrome (1.1%, n=2).  Similar to 
most other SCAs discussed thus far, neither pregnancy demonstrated abnormalities.  Both 
mothers declined prenatal diagnosis, and one declined postnatal testing. 
PH-USC 65 declined postnatal testing because she reported her daughter is 
meeting all developmental milestones.  This suggests that parents may not feel it is 
necessary to test in the absence of typical features.  This may especially be the case in 
SCAs, since the clinical symptoms include increased risks for social and developmental 
challenges as opposed to significant medical complications.   
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Maternal mosaicism could be an explanation for either abnormal result, however, 
PH-USC 65 had a normal karyotype secondary to personal history of pregnancy loss.  
2.5.8 Microdeletions 
We had a small sample size of screen positive microdeletions, all for 22q11.2 
deletion syndrome (1.7%, n=3).  This is not surprising given the overall low prevalence 
of these conditions, as well as the fact that they are usually an opt-in when available on 
standard NIPS.   
All three patients declined prenatal diagnosis, although one patient, PH-USC 96, 
received a result indicating a suspected maternal finding and opted for maternal 
microarray.  The result confirmed the presence of a pathogenic 22q11.2 deletion.  The 
other two patients (PH-USC 135 and PH-G 8) had pregnancies that each demonstrated 
TOF, a conotruncal defect known to be associated with 22q deletion syndrome.  Postnatal 
testing confirmed the diagnosis for both infants.    
The case of PH-USC 96 highlights the importance in distinguishing between a 
maternal and fetal result, as this information guides post-test counseling.  As seen in this 
case and other maternally-indicated results, patients express greater comfort levels in 
having blood karyotypes rather than invasive prenatal testing.    
 2.5.9 No call- low fetal fraction 
 No call- LFF made up 11.6% of our abnormal results (n=21).  We identified 
several patterns consistent with other literature.  First, most patients receiving this result 
were over 240 pounds, even after adjusting for singleton vs. twin gestations.  Similarly, 
as maternal medications and/or comorbidities have been described in correlation with 
LFF results, nearly a quarter of our patients met this criteria.  All patients with 
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documented medication use or other comorbidities had at least two LFF results, and only 
one of them eventually received a low risk result.  One patient with a successful redraw 
was initially screened at nine weeks gestation.  While nine weeks and beyond is an 
acceptable gestational age for NIPS, this early gestational age likely resulted in a LFF 
result.  Fetal fraction continues to increase as the pregnancy progresses, which likely 
explains why this patient had a successful redraw (Benn, Valenti, Shah, Martin & 
Demko, 2018).  Several of our results were produced by twin gestations, and it is known 
that multiple gestations have a higher fail rate than singletons due to a lower average FF 
per twin (Galeva, Gil, Konstantinidou, Akolekar, & Nicolaides, 2019; Gil, et al., 2015; 
Qiao et al., 2019).  This likely explains why only one patient expecting twins opted for a 
redraw.  Hemoglobinopathies are a newer area of interest when considering LFF results, 
however, these did not apply to any of our patients (Putra et al., 2019).  Nevertheless, we 
were able to make attributions for the majority of our LFF results. 
 Considering redraws, our informative redraw rate of 46.2% was slightly below 
what has been described in the literature (Benn, Valenti, Shah, Martin & Demko, 2018; 
Galeva, Gil, Konstantinidou, Akolekar, & Nicolaides, 2019; Suzumori et al., 2019; 
White, Wang, Kunz, & Schmid, 2019).  This could be due to higher maternal weights and 
more comorbidities in our population that work against the chance for a successful result.  
As those that had an informative redraw weighed slightly less than those with 
uninformative redraws and had no medication use or comorbidities, it seems these are 
important factors.     
 Uptake of diagnostic testing was low in this cohort, and three patients were lost to 
follow-up after normal MSS.  Though used by these patients for reassurance, it should be 
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noted that MSS is not the most appropriate or informative follow-up.  There is an 
increased risk for all aneuploidy with a LFF result, and in the case of these patients, they 
were only screened for T21 and T18 through quad screening.   
Four patients, including one with ultrasound findings, were lost to follow-up.  PH-
USC 1 received two no calls beginning at 24 weeks gestation.  Fetal fraction was not 
given on either report.  Her fetus had unilateral club foot and CPCs identified on 
ultrasound, however, she declined all further testing and screening and could not be 
reached when contacted for our study.   
PH-USC 63 was successfully contacted for a phone interview.  She was 43 years 
old at delivery and weighed 280 pounds at the time of screening.  She received two LFF 
results from Natera beginning at 14 weeks.  She reported that her daughter was diagnosed 
with transposition of the great arteries (TGA) at birth but is otherwise normal.  We were 
not able to make a classification based on the lack of postnatal genetic testing. 
We could confirm that two of our patients with abnormalities ultimately had non-
aneuploid outcomes.  PH-USC 10 had four LFF results and a positive MSS for T21 
before receiving a low risk NIPS result at 20 weeks.  She weighed 240 pounds, was a 
lovenox user, and also suffered autoimmune disease.  Her fetus demonstrated IUGR and 
oligohydramnios on ultrasound, but ultimately had a normal female karyotype.  No CMA 
was performed.  PH-USC 71, weighing 149 pounds, had one LFF result at 10 weeks and 
demonstrated an increased nuchal translucency (NT) during her late-trimester scan.  She 
elected to pursue CVS which revealed a normal female karyotype and microarray.  A 
second trimester MS-AFP also returned normal.  These two patients are similar to the 
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T18/T13 patients with abnormalities but normal karyotypes, reiterating the significance 
of diagnostic testing for confirming or ruling out aneuploidy.    
Two of the patients lost to follow-up did not have clear reasons for LFF.  PH-USC 
11 received two no calls beginning at 13 weeks.  Fetal fraction was not given on either 
report.  She weighed 188 pounds and had no comorbidities or medication use.  Her 
second trimester ultrasound was unremarkable, and she also had normal MSS before 
being lost to follow-up.  This was uninformative as MSS only screens for trisomies 21 
and 18.  PH-USC 74 had two no calls beginning at 12 weeks.  Fetal fraction was not 
given on her report.  She weighed 158 pounds and also had no comorbidities or 
medication use.  An early second trimester scan was unremarkable before she was lost to 
follow-up.   
2.5.10 High risk for triploidy, trisomy 18, or trisomy 13 due to LFF 
High risk for Triploidy, Trisomy 18, or Trisomy 13 due to LFF made up 10.5% of 
our abnormal results (n=19).  This result is generated after the laboratory cannot correlate 
low fetal fraction with maternal weight, maternal age, or gestational age.  Indeed, all 
three means of these categories fell below what was observed in general LFF results, 
which is consistent with data produced by the performing laboratory (Benn et al., 2019).  
Similar to T13, most declined diagnostic testing in the absence of ultrasound 
abnormalities.  This was surprising given the complexity of this result type as well as the 
poor prognoses for all three conditions.  The relationship between ultrasound findings 
and uptake of diagnostic testing most resembled T18, as two of the three patients who 
elected amniocentesis had abnormalities.   
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The unique circumstances of two cases further emphasized the importance of 
diagnostic testing, as they ended up with findings outside the scope of their results.  PH-
USC 29 opted for MSS that indicated a 1/10 chance for T21, and subsequent 
amniocentesis confirmed a 47,XX,+21 karyotype.  This was a surprising finding given 
the high sensitivity for T21 on NIPS, however, as part of this result type, she was not 
given a result for chromosome 21.  PH-USC 92 received her abnormal result at 16 weeks, 
and ultrasound at that time revealed an EIF and a ventricular septal defect (VSD).  
Amniocentesis ruled out aneuploidy but incidentally found a maternally-inherited 
duplication of 20p13.  Again, her case is an example of how ultrasound abnormalities can 
be used in risk assessment for an abnormal result, but ultimately diagnostic testing is 
essential for confirming or ruling it out. 
Though Natera recommends against a redraw for this type of result, seven patients 
attempted.  Nearly half of them were successful in getting a low risk result the second 
time, and that number is in agreement with the rate of successful LFF redraws.  This 
scenario presents a couple of possibilities: 1) the pregnancy is truly low risk, or 2) there is 
another genetic aberration, potentially one not covered by the scope of the test.  As we 
saw in the case of PH-USC 29, whose pregnancy with T21 was missed by Natera calling 
this result, diagnostic testing was the most informative next step in risk assessment.  
Patients opting to redraw should be cautioned on the limitations and potential for false 
reassurance in receiving a low risk result.   
 2.5.11 No call- uninformative DNA pattern 
 A no call- UDP result made up 5.5% of our results (n=10).  Out of all no call 
results, uptake of diagnostic testing was highest in this category, and all who opted for 
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prenatal diagnosis did so in the absence of ultrasound abnormalities.  As a result, three 
genetic aberrations across four abnormal outcomes were identified. 
 PH-USC 13 was a 28 year old G2P1001 who had two UDP results in the second 
trimester.  Ultrasounds revealed a cystic hygroma (resolved), Dandy Walker 
malformation, overriding aorta, cleft lip, hand/foot syndactyly, hypertelorism, and a short 
philtrum.  The pregnancy ended in demise at 24 weeks.  Postnatal studies revealed a 
normal 46,XY karyotype.  Reflex to whole exome sequencing (WES) revealed a maternal 
variant in FANCD2 and a paternal variant in WASHC5.  These changes were classified as 
VUS; therefore, conclusions related to the observed phenotype were not made. 
 PH-USC 47 was a 25 year old G2P0010 who received a UDP result at the end of 
her first trimester.  She opted for amniocentesis that returned a 46,XY karyotype, 
however, maternal cell contamination studies revealed XXX mosaicism.  She was 
counseled that this was the most likely explanation for her UDP result.  
 PH-USC 57 was a 31 year old G3P0020 that received two UDP results in the 
second trimester.  In the presence of a normal ultrasound, she declined diagnostic testing 
and instead opted for MSS that was normal.  The pregnancy ended in demise at 20 weeks 
and no further testing was performed.  Similar to patients receiving general no call- LFF 
results, this patient opted for MSS as the next step in risk assessment, and likely used the 
normal results for reassurance.  It should be noted that MSS was not the most appropriate 
or informative follow-up in this result type, either, as she was provided risk assessment 
for only two chromosome conditions.  Interestingly, the patient has a diagnosis of focal 
segmental glomerulosclerosis and is status-post unilateral kidney transplant.  Maternal 
kidney disease has been described in correlation with abnormal NIPS results, especially 
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in the setting of a transplant, but not necessarily fetal demise (Neufeld-Kaiser, Cheng, & 
Liu, 2015).  Studies on the fetus would have been most informative, however, it may 
have been appropriate to also offer karyotype and microarray to the patient given her 
history of two prior losses. 
 PH-USC 85 was a 16 year old G1P0 who received a UDP result late in the second 
trimester after polyhydramnios and dilated bowel were identified on ultrasound.  She 
declined diagnostic testing and opted for NIPS on a genome-wide platform as well as 
expanded carrier screening, both of which returned normal.  The pregnancy ended in 
demise at 35 weeks.  It was later determined that this patient’s pregnancy was the result 
of sexual assault by a first-degree male relative.  Consanguinity could be the explanation 
for the uninformative result as well as the poor outcome of the fetus.   
 Overall, three of our four cases of interest had outcomes concurrent with what has 
been put forth as explanations for UDP results.  Maternal genetic aberrations, maternal 
comorbidities, and consanguinity have all been presented as explanations for this type of 
no call.  Consideration of PH-USC 13’s two abnormal results, remarkable ultrasounds, 
and poor fetal outcome suggests that an underlying genetic condition is likely 
responsible, however, testing was not able to definitively identify it.   
Compared to patients receiving other types of no call results, patients with UDP 
results had pregnancies associated with more abnormalities and/or adverse outcomes.  
This suggests that diagnostic testing is the most informative follow-up in the setting of 
this result.  This includes maternal testing, as one of our significant outcomes related to a 
maternal diagnosis.  It is also telling that the two patients opting for redraw received a 
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second failure, suggesting that waiting for more advanced gestational age may not be the 
solution that can sometimes apply to LFF results.   
2.5.12 No call- triploidy, vanishing twin, or unrecognized multiple gestation 
 In our study, 2.8% of our patients received this type of result, which is generated 
after the detection of three DNA patterns (n=5).  We were able to identify two patients 
with outcomes related to this call.  PH-USC 12 was a 25 year old G2P1001 who received 
her result after ultrasound revealed a placental mass.  As she also had a normal-appearing 
male fetus, the mass was felt to be a molar pregnancy and the reason for the abnormal 
result.   
 PH-G 7 was a 36 year old G4P2012 who received an abnormal result at 22 weeks.  
A genetic counselor at the performing laboratory inquired with the clinician as to whether 
or not the patient was pregnant with twins.  As she was late to prenatal care and had not 
yet had an ultrasound, this was unknown.  Subsequent ultrasound revealed twins, 
providing the reason for the abnormal result.   
 Outcome performance for this result type is difficult to adequately assess due to 
the possibility of vanishing twins.  At least from our data, however, there were no adverse 
fetal outcomes.  
 2.5.13 Other results 
 Other results categorized by multiple abnormalities or other types of no calls, 
including those on a genome-wide platform (8.3%, n=15).  For this cohort, uptake of 
maternal chromosome analysis was higher than prenatal diagnosis, despite only two 
results specifically indicating a maternal abnormality.  This is similar to the cohort of 
patients screen positive for a microdeletion, in which the distinction between a maternal 
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or fetal result was helpful in post-test counseling and ultimately, patients choosing their 
follow-up management.  As a result, all of our diagnoses were made in mothers.   
PH-USC 61 was a 24 year old G4P1021 who received a no call- abnormal 
maternal X result from Natera at 12 weeks gestation.  She opted for chromosome analysis 
which returned a mosaic 45,X karyotype, a likely explanation for her history of 
pregnancy loss.  At the time of our project’s completion, she was still pregnant with an 
apparently normal male fetus.   
PH-USC 142 was a 34 year old G2P1001 who received a no call- atypical finding 
result at 12 weeks gestation.  This no call result generated by Natera did not specify 
suspected maternal or fetal.  A phone call to a genetic counselor at Natera revealed 
chromosome 13 as the region of interest.  In the absence of ultrasound abnormalities, the 
patient opted for maternal chromosome analysis which returned a 13q12.12 deletion 
(VUS).  At the time of our study’s completion, she was still pregnant and had declined 
diagnostic testing for her female fetus.  This case reiterates the significance of calling the 
laboratory for more information.  The patient was able to learn the reason for her 
abnormal result and make informed decisions on follow-up and management.  
 PH-USC 145 was a 28-year-old G2P1001 who received a no call- atypical sex 
chromosomes result from Natera at 13 weeks gestation.  The laboratory report did not 
specify suspected maternal or fetal.  Similar to PH-USC 142, this patient opted for 
maternal chromosome analysis in the absence of ultrasound abnormalities.  Karyotype 
revealed an unbalanced translocation between chromosomes Xq and 3q.  This 
rearrangement typically results in normal females due to X-inactivation, but features such 
as premature ovarian failure have been reported.  It is lethal in males.  At the time of our 
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project’s completion, she was still pregnant and had declined diagnostic testing for her 
female fetus.   
 We also had several patients that received double screen positive results.  In the 
cases of two patients, their pregnancies ended in IUFD without further testing.  PH-USC 
140 was a 44-year-old G3P2002 who received one result from Progenity indicating both 
T18 and Monosomy X.  When she presented to our clinic at 13 weeks, it was discovered 
that the pregnancy had ended in demise.  Given the screen positives and loss, it is likely 
that the fetus had one or both of these conditions.  PH-G 29 was a 45 year old G1P0 who 
received separate abnormal results from Natera: first, a high risk for Triploidy, T18, or 
T13 due to LFF at 11 weeks gestation, and second, a screen positive T21 at 14 weeks.  
The fetus showed a single umbilical artery before miscarrying at 22 weeks.  If the fetus 
indeed had T21, it would be the second in our data set that was initially called high risk 
for Triploidy, T18, or T13 due to LFF.    
We also had three patients who all received both a no call- LFF and high risk for 
Triploidy, T18, or T13 due to LFF result from Natera.  In each case, the general LFF call 
resulted first.  None of the patients were AMA, and their screening was performed within 
the specified timeframe.  The mean maternal weight was 239 pounds, suggesting 
increased body habitus as a contributing factor.  LFF may have been called initially, and 
then the high risk for Triploidy, T18, or T13 algorithm was triggered as the result of all 
patients being below AMA and attempting their redraws well into their second trimesters.  
This theory is based on the observation that waiting for more advanced gestational age 
can sometimes “correct” issues from borderline maternal weights that initially prohibit a 
result (Benn et al., 2018).   
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Within this same cohort of two different LFF results, the case of PH-USC 60 was 
interesting.  She was a 30 year old G2P1001 that was born with bilateral syndactyly of 
her hands and feet in addition to shortened and absent long bones.  She had also been 
newly diagnosed with hypertrophic cardiomyopathy.  She reported that a genetic 
evaluation in childhood attributed her features to amniotic band syndrome.  In our 
practice, she was counseled that this was unlikely and was recommended to have a 
second evaluation, however, she declined.  Given her unique features it is possible that 
she has an underlying condition that contributed to her abnormal results.  At the close of 
our study, she had just given birth to a normal male infant.   
 Several patient outcomes were unavailable at the close of our study.  Two of these 
results, PH-G 24 and PH-G 28, were generated by Counsyl’s genome-wide platform and 
involved chromosome 19 aneuploidy.  Both patients were followed with normal 
ultrasounds until 20 and 38 weeks, respectively, before they were lost to follow-up.  It is 
possible these results were placental in origin, as full chromosome 19 aneuploidy would 
not be compatible with life.  Another patient, PH-USC 49, received two no call- multiple 
aneuploidy results from Progenity in her second trimester.  The laboratory report did not 
specify chromosomes of interest.  Tragically, this patient died of cardiac arrest and her 
daughter was delivered via emergency cesarean at 27 weeks gestation.  We were unable 
to determine if the infant had complications beyond that of prematurity.   
2.6 Limitations and future research  
 2.6.1 Limitations 
 Our patient population was primarily composed of Caucasian and African 
American individuals and our data originates from two high risk obstetric clinics in South 
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Carolina.  This uniformity in demographics may mean our performance data could not 
extend to other populations.   
 Overall, outcome data was limited by a significant portion of our patients being 
lost to follow-up or having IUFDs without testing to confirm a diagnosis.  Though many 
of the pregnancies ending in demise had abnormalities related to their abnormal results 
and were likely true positives, we were unable to classify them as such due to the lack of 
confirmatory testing.  
We were unable to find commonalities in patients that might serve as novel 
correlations for LFF results, though we observed many well-described associations: 
increased maternal weight; comorbidities such as diabetes, autoimmune disease, and 
hypertension; maternal use of blood thinners; and early gestational age.   
 Considering genetic testing and management, we identified cases that would have 
benefitted from both karyotype and microarray analysis.  This came to attention when we 
discovered that a screen positive T21 was actually a partial duplication of chromosome 
21.  We also had a non-AMA patient with two pregnancies screen positive for T21, and 
she only had karyotype.  As many of our false positives were classified after karyotype-
only, underlying copy number variants cannot be ruled out.  
  Frequency of ultrasound abnormalities was an important statistic for each of our 
result types.  As several patients were not followed in our clinic throughout the duration 
of their pregnancies, we were often reviewing only one or two ultrasound reports that 
may not have represented the best window for visualizing abnormalities.  It is possible 
that ultrasound findings were detected after patients’ last visits to our clinic.   
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 We also had a small sample for certain conditions, namely XXY, XYY, XXX, 
and microdeletions.  This was not surprising given that the detection rates for these 
conditions are not well established, and many patients and providers opt out of 
microdeletion screening.  Additionally, several of our no calls were newer types that 
began resulting during the course of our study, which meant we had a small sampling of 
each.  Completing this study over a longer period of time would have produced a larger 
sample of these underrepresented result types.   
 Finally, while most of our outcomes were classified by data in the EMR, several 
were by patient report.  We did not require reports from patients to confirm or rule-out a 
diagnosis; therefore, it is possible that we unintentionally factored in false information to 
our data. 
  2.6.2 Future research 
 Other clinics are encouraged to track their own abnormal screening outcome data 
in order to evolve the definition and outcomes of no call results.  Future research could 
also target conditions we had low representation of, such as SCAs and microdeletions.  
Though included on NIPS platforms for some time, they are still underperforming 
compared to autosomal aneuploidies.  More research could add to the continuing 
conversation on appropriate management and follow-up. 
 It has been long recognized that presumed false positive serum analyte screening 
via normal ultrasound or declined diagnostic testing is associated with an increased risk 
for a poor perinatal and/or maternal outcome.  The same association has been suggested 
with abnormal NIPS (both presumed true and false positives), LFF, and other no call 
results for other reasons.  While the numbers in the current study are small, the data does 
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suggest an increased risk for poor perinatal outcomes (growth abnormalities, structural 
abnormalities, and fetal demise).  Given these results, several clinical recommendations 
can be considered as part of routine obstetrical care in these patients.  These include serial 
ultrasound examinations for growth, assessment of anatomy and fetal viability, and 
consideration of antenatal testing for fetal wellbeing in the third trimester. 
As data become available from future studies, these management recommendations can 
be further refined. 
Though not the primary goal of the study, our data in large part was an evaluation 
of patients’ decision-making and handling of abnormal results.  Generalizations are 
difficult to make knowing each patient’s decisions are highly situational and specific to 
their own wants, needs, and values.  As a result, future research could also include their 
perspectives on receiving abnormal results, and what factors are important in their 
decision-making process moving forward.   
2.7 Conclusion 
 As coverage of NIPS platforms continues to evolve, research on performance and 
outcomes will need to stay active as professional guidelines seek to establish clear 
follow-up and management recommendations.  Data from clinics contribute to outcome 
statistics that are usually supplied by performing laboratories.  As such, data from 
individual clinics limits bias in what laboratories publish about their work, and it 
challenges them to continue improving NIPS so that it is the most accurate and specific it 
can be.  Clinics also benefit from considering their outcome data and using that 
information to develop management guidelines for results that will undoubtedly occur 
again, as we did in our study.  While research should continue both in frequency and 
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expansion, this outcome data is valuable not only for our own practice but also other 
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Table 3.1 Patients with abnormal results and ultrasound findings, but normal karyotypes 
 
 
Table 3.2 Maternal diagnoses after abnormal NIPS results  
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LETTER INVITATION TO PARTICIPANTS 
Dear Ms. X: 
 
 
My name is Olivia Kesler, and I am a senior genetic counseling student at the University 
of South Carolina.  I am conducting a research study as part of the requirements of my 
Master’s degree, and I would like to include your participation.  
I am studying the pregnancy outcomes of abnormal NIPS, or non-invasive prenatal 
screening results.  My training program is in the same office you met with a genetic 
counselor about your abnormal results sometime during 2018 or 2019.  This screening 
seeks to inform women if they have a higher risk of having a child with certain genetic 
conditions such as Down syndrome.  Occasionally, the screening may also fail to give a 
result.         
In particular, you will be asked questions about the outcome of your pregnancy.  You 
may have had further testing that was done to confirm or rule out what the screening said 
could be a possibility for your pregnancy.  You do not have to answer any questions that 
you do not wish to answer.  It is expected that answering these questions would not take 
longer than 5-10 minutes of your time.  
I plan to contact you by phone on Thursday, November 21, 2019, between 12 PM – 5 
PM.  If you do not wish to participate, please contact the genetic counseling office by 
phone at 803-545-5775 to opt out.   
Participation is confidential.  Study information will be kept in a secure location at the 
University of South Carolina.  The results of the study may be published or presented at 
professional meetings, but your identity will not be revealed.  
We will be happy to answer any questions you have about the study.  You may contact 
me by phone at 803-545-5775, by email at olivia.kesler@uscmed.sc.edu, or my faculty 
advisor, Jessica Fairey, by phone at 803-545-5746, or by email at 
jessica.fairey@uscmed.sc.edu.  
 
       With kind regards, 
       Olivia Kesler  
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